Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double‐blind placebo‐controlled trial
Clinical & Experimental Allergy2021Vol. 51(6), pp. 836–844
Citations Over TimeTop 1% of 2021 papers
Abstract
Benralizumab was well-tolerated and compared with baseline achieved a statistically significant reduction in nasal polyp size, sinus occupancy, symptoms and improved sensation of smell for most patients (83%).
Related Papers
- → Relationship between Postoperative Recurrence Rate and Eosinophil Density of Nasal Polyps(2010)116 cited
- → Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset(2018)76 cited
- Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient.(1999)
- → Assessment of the blood eosinophil count in different grades of nasal polyps(2022)3 cited
- [Expressions of IL-13 and IL-13Rα2 in eosinophilic chronic rhinosinusitis with nasal polyps and clinical implications].(2015)